Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
20. Dezember 2021 07:59 ET
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
Exactus, Inc. Signs Cool & Dre Endorsement and Co-Branding Deal
26. November 2019 06:30 ET
|
Exactus, Inc.
DELRAY BEACH, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB:EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today...
Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment
14. Februar 2018 07:00 ET
|
Regentys
MIAMI LAKES, Fla., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Regentys (formerly Asana Medical, Inc.), a regenerative medicine company, today announced it will partner with Cook Biotech Inc., a world leader...
Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100
17. Januar 2018 08:00 ET
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC
03. Januar 2018 08:30 ET
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis
30. Mai 2017 08:00 ET
|
Atlantic Healthcare plc
CAMBRIDGE, U.K., May 30, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...
Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication
22. Mai 2017 08:00 ET
|
Atlantic Healthcare plc
CAMBRIDGE, U.K., May 22, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...
Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
11. Juni 2013 16:22 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Early Diagnosis and Public Awareness of Crohn's and Ulcerative Colitis Critical to Patient Care
23. November 2011 09:00 ET
|
Crohn's & Colitis Foundation of Canada (CCFC)
TORONTO, ONTARIO--(Marketwire - Nov. 23, 2011) - Imagine experiencing agonizing and debilitating pain that lasts for hours, months and even a year without a Doctor or Medical Practitioner...